Alembic Pharmaceuticals Share Price

743.358.71 (1.19%)

Closed
As On: 12 Jun, 2026, 03:55 PM IST
As On: 12 Jun, 2026, 03:40 PM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Open	749.25
High	754.45
Low	738.30
Prev Close	734.65
Volume	86,226
VWAP(₹)	743.98

Share Price	Value
Today/Current/Last	743.35739.95
Previous Day	734.65735.00

Alembic Pharma Share Recommendations

Mean recosCurrent

BUY

9 Analysts

Strong
SellSellHoldBuyStrong
Buy

Analyst Trends

Ratings	Current	1W Ago	1M Ago	3M Ago
Strong Buy	3	3	3	4
Buy	1	1	1	2
Hold	5	5	5	5
Sell	-	-	-	-
Strong Sell	-	-	-	1
# Analysts	9	9	9	12

Recent Recos

Target₹660
OrganizationJM Financial
HOLD

Target₹653
OrganizationICICI Securities
BUY

Target₹730
OrganizationJM Financial
HOLD

View all Stock Recommendations

News & Analysis

Stocks in news: Wipro, HUL, Angel One, Alembic Pharma, HDFC Life
News
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcements
Announcement under Regulation 30 (LODR)-Credit Rating
Announcements
Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcements

View all Alembic Pharma Share News & Announcements

Financials

Income (P&L)

	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024
Total Income	1,891.81	1,917.06	1,717.22	1,783.83	1,702.24
Total Income Growth (%)	-1.32	11.64	-3.73	4.79	2.25
Total Expenses	1,705.17	1,670.53	1,503.14	1,566.70	1,502.56
Total Expenses Growth (%)	2.07	11.14	-4.06	4.27	2.47
EBIT	186.64	246.53	214.08	217.13	199.68
EBIT Growth (%)	-24.29	15.16	-1.40	8.74	0.66
Profit after Tax (PAT)	132.97	184.71	154.38	156.89	138.42
PAT Growth (%)	-28.01	19.65	-1.60	13.34	-9.77
EBIT Margin (%)	9.87	12.86	12.47	12.17	11.73
Net Profit Margin (%)	7.03	9.64	8.99	8.80	8.13
Basic EPS (₹)	6.76	9.40	7.85	7.98	7.01

	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024
Total Income	1,652.97	1,807.73	1,501.96	1,583.85	1,421.55
Total Income Growth (%)	-8.56	20.36	-5.17	11.42	-10.95
Total Expenses	1,492.54	1,568.57	1,353.80	1,468.58	1,295.95
Total Expenses Growth (%)	-4.85	15.86	-7.82	13.32	-5.96
EBIT	160.43	239.16	148.16	115.27	125.60
EBIT Growth (%)	-32.92	61.42	28.53	-8.22	-42.46
Profit after Tax (PAT)	114.47	179.36	103.52	75.34	85.81
PAT Growth (%)	-36.18	73.26	37.40	-12.20	-48.24
EBIT Margin (%)	9.71	13.23	9.86	7.28	8.84
Net Profit Margin (%)	6.93	9.92	6.89	4.76	6.04
Basic EPS (₹)	5.82	9.12	5.27	3.83	4.37

	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	6,714.63	6,256.93	5,655.36	5,356.25	5,403.15
Total Revenue Growth (%)	7.32	10.64	5.58	-0.87	17.19
Total Expenses	6,021.19	5,624.13	5,269.84	4,736.14	4,035.07
Total Expenses Growth (%)	7.06	6.72	11.27	17.37	13.12
Profit after Tax (PAT)	583.42	615.82	341.99	520.94	1,178.11
PAT Growth (%)	-5.26	80.07	-34.35	-55.78	42.14
Operating Profit Margin (%)	11.57	11.06	7.70	12.02	25.66
Net Profit Margin (%)	8.74	9.88	6.05	9.81	21.84
Basic EPS (₹)	29.68	31.33	17.40	26.50	60.81

	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	6,080.51	5,905.38	5,152.54	5,086.55	5,061.17
Total Revenue Growth (%)	2.97	14.61	1.30	0.50	18.60
Total Expenses	5,484.79	5,201.15	4,806.60	4,428.55	3,644.58
Total Expenses Growth (%)	5.45	8.21	8.54	21.51	17.93
Profit after Tax (PAT)	503.12	666.48	346.73	543.55	1,175.39
PAT Growth (%)	-24.51	92.22	-36.21	-53.76	21.25
Operating Profit Margin (%)	11.14	12.91	7.67	13.40	28.29
Net Profit Margin (%)	8.33	11.34	6.73	10.79	23.26
Basic EPS (₹)	25.60	33.91	17.64	27.65	60.67

All figures in Rs Cr, unless mentioned otherwise

Insights

Employee & Interest Expense
Company has spent 1.27% of its operating revenues towards interest expenses and 23.58% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

View Details

Balance Sheet

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Assets	7,772.94	6,445.58	6,182.83	7,122.03	6,708.98
Total Assets Growth (%)	20.59	4.25	-13.19	6.16	12.02
Total Liabilities	2,583.41	1,627.38	1,812.36	1,884.49	1,642.01
Total Liabilities Growth (%)	58.75	-10.21	-3.83	14.77	-41.33
Total Equity	5,189.53	4,818.20	4,370.47	5,237.54	5,066.97
Total Equity Growth (%)	7.71	10.24	-16.55	3.37	58.82
Current Ratio (x)	1.69	2.12	1.78	1.67	2.01
Total Debt to Equity (x)	0.23	0.09	0.15	0.12	0.04
Contingent Liabilities	189.48	183.13	317.96	228.15	349.23

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Assets	7,556.27	6,398.54	6,130.42	7,074.04	6,776.18
Total Assets Growth (%)	18.09	4.37	-13.34	4.40	15.27
Total Liabilities	2,361.53	1,489.63	1,716.13	1,783.70	1,521.94
Total Liabilities Growth (%)	58.53	-13.20	-3.79	17.20	-39.91
Total Equity	5,194.74	4,908.91	4,414.29	5,290.34	5,254.24
Total Equity Growth (%)	5.82	11.20	-16.56	0.69	57.03
Current Ratio (x)	1.71	2.25	1.79	1.74	2.11
Total Debt to Equity (x)	0.22	0.09	0.14	0.12	0.04
Contingent Liabilities	240.49	193.55	326.18	228.15	327.06

All figures in Rs Cr, unless mentioned otherwise

View Details

Cash Flows

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash flow from Operating Activities	87.97	803.20	723.95	552.36	1,463.38
Net Cash used in Investing Activities	-568.41	-320.61	-447.59	-371.97	-838.81
Net Cash flow from Financing Activities	443.71	-437.86	-261.96	-217.36	-597.42
Net Cash Flow	-36.73	44.73	14.40	-36.97	26.22
Closing Cash & Cash Equivalent	83.48	120.21	75.48	61.09	98.06
Closing Cash & Cash Equivalent Growth (%)	-30.55	59.26	23.56	-37.70	36.50
Total Debt/ CFO (x)	13.59	0.54	0.88	1.14	0.14

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash flow from Operating Activities	226.57	772.77	730.25	545.26	1,485.30
Net Cash used in Investing Activities	-636.08	-329.02	-460.98	-368.72	-925.55
Net Cash flow from Financing Activities	403.61	-445.29	-261.16	-216.64	-533.60
Net Cash Flow	-5.90	-1.54	8.11	-40.10	25.22
Closing Cash & Cash Equivalent	14.23	20.13	21.67	13.56	53.44
Closing Cash & Cash Equivalent Growth (%)	-29.31	-7.11	59.81	-74.63	89.37
Total Debt/ CFO (x)	5.04	0.54	0.87	1.16	0.13

All figures in Rs Cr, unless mentioned otherwise

Insights

Decrease in Cash from Investing
Company has used Rs 506.05 cr for investing activities which is an YoY decrease of 10.97%. (Source: Consolidated Financials)

View Details

Ratios

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Return on Equity (%)	11.23	12.78	7.82	9.94	22.97
Return on Capital Employed (%)	14.40	13.80	9.58	11.79	25.49
Return on Assets (%)	7.50	9.55	5.53	7.31	17.56
Interest Coverage Ratio (x)	13.34	17.11	14.17	52.15	86.40
Asset Turnover Ratio (x)	0.94	0.99	0.78	0.73	80.38
Price to Earnings (x)	31.35	31.45	28.57	28.01	16.10
Price to Book (x)	3.52	4.01	2.23	2.78	3.70
EV/EBITDA (x)	18.43	20.39	14.49	16.37	12.12
EBITDA Margin (%)	15.74	15.43	12.58	17.42	29.06

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Return on Equity (%)	9.68	13.57	7.85	10.27	22.37
Return on Capital Employed (%)	12.54	14.96	8.62	12.28	25.28
Return on Assets (%)	6.65	10.41	5.65	7.68	17.34
Interest Coverage Ratio (x)	12.41	18.91	13.63	56.40	111.93
Asset Turnover Ratio (x)	0.86	0.94	0.78	0.73	74.54
Price to Earnings (x)	36.36	28.99	28.17	26.81	16.16
Price to Book (x)	3.52	3.93	2.21	2.75	3.61
EV/EBITDA (x)	20.42	19.13	15.50	15.81	12.08
EBITDA Margin (%)	15.73	17.53	12.97	19.06	31.31

Found Financials useful?

5 Days	14 Days	28 Days
24.24	25.08	25.15

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Alembic Pharma	21.65	2.58	11.89	13.84	7.70	9.28	11.63	9.13	34.33	1.76	0.24	1.74
Wockhardt	147.84	5.96	4.31	7.66	2.47	7.82	15.89	5.89	13.12	1.66	0.43	5.45
Sai Life Science Ltd.	73.94	10.39	14.04	18.38	9.62	21.41	23.41	15.91	16.63	1.69	0.04	0.19
Neuland Labs	60.62	11.77	19.41	23.10	12.42	19.36	25.35	17.99	283.71	2.09	0.10	0.57
Eris Lifesciences	31.41	5.00	15.87	16.04	8.41	22.50	27.10	20.68	45.33	0.74	0.59	4.29
Add More

Annual Ratios (%)

Choose from Peers

OneSource Specialty
Caplin Point
Aarti Inds
Jubilant Life
Natco Pharma

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

NAME	1D	1W	1M	3M	1Y	3Y	5Y
Alembic Pharma Stock Performance	1.19	-5.39	-2.74	-2.58	-22.72	34.82	-22.28
Wockhardt Stock Performance	0.74	25.26	37.67	40.27	44.50	1042.02	184.25
Sai Life Science Ltd. Stock Performance	3.13	9.49	27.06	29.39	64.51	0.00	0.00
Neuland Labs Stock Performance	1.33	3.11	15.27	36.08	53.64	507.35	686.91
Eris Lifesciences Stock Performance	2.86	2.23	2.08	4.63	-6.73	126.02	98.19
Add More

Found Peer Comparison useful?

Category	No. of Shares	Percentage	% Change QoQ
Promoters	13,70,81,813	69.74 %	0.00
Pledge	0	0.00 %	0.00
FII	83,61,504	4.26 %	0.02
DII	3,17,47,127	16.14 %	0.00
MF	1,60,83,228	8.18 %	-0.04
Others	1,93,72,680	9.86 %	-0.03

Category	Mar 2026	Dec 2025	Sep 2025	Jun 2025
Promoters	69.74	69.74	69.74	69.67
Pledge	0.00	0.00	0.00	0.00
FII	4.26	4.23	4.04	3.96
DII	16.14	16.14	16.27	16.43
Mutual Funds	8.18	8.22	8.55	9.05
Others	9.86	9.89	9.95	9.93

Mutual Funds Ownership

MF Ownership as on 30 April 2026

Kotak Small Cap Direct-G
Equity: Small Cap
2
- 258.80
  Amount Invested (in Cr.)
- 1.49%
  % of AUM
- 0.00
  % Change (MoM basis)
DSP Midcap Direct-G
Equity: Mid Cap
2
- 160.28
  Amount Invested (in Cr.)
- 0.82%
  % of AUM
- 0.00
  % Change (MoM basis)
ICICI Pru Pharma Healthcare and Diagnostics (P.H.D) Direct-G
Equity: Sectoral-Pharma
4
- 116.37
  Amount Invested (in Cr.)
- 1.74494844%
  % of AUM
- 0.00
  % Change (MoM basis)

View all Mutual Fund Schemes

Alembic Pharma Futures & Options

Options
Futures
- Expiry MonthPlease select expiry month:
Date Price Open Interest
-- (-%)
-- (-%)
-
Open
-
High
-
Low
-
Prev Close
-
Contracts Traded
-
Turnover (₹ Lakhs)
Open Interest as of

Date	Price	Open Interest
	-- (-%)	-- (-%)
- Open	- High	- Low
- Prev Close	- Contracts Traded	- Turnover (₹ Lakhs)

Corporate Actions

Recent
Board Meeting
Quarterly Results
Jan 20, 2026
Board Meeting
Quarterly Results & Others
Oct 23, 2025
Board Meeting
Quarterly Results & Others
Jul 21, 2025

Board Meetings

Announced on	Meeting on
Jan 20, 2026	Feb 05, 2026
Quarterly Results
Oct 23, 2025	Nov 04, 2025
Quarterly Results & Others
Jul 21, 2025	Aug 05, 2025
Quarterly Results & Others
Apr 21, 2025	May 06, 2025
Audited Results & Final Dividend
Jan 23, 2025	Feb 03, 2025
Quarterly Results & Others

Dividends
Announced on Ex-Date Dividend%
May 06, 2025 Jul 29, 2025 550%
May 09, 2024 Jul 15, 2024 550%
May 05, 2023 Jul 28, 2023 400%
May 02, 2022 Aug 17, 2022 500%
May 02, 2022 - 500%
Bonus
No Data Available
Splits
No Data Available
Rights
No Data Available
AGM/EGM Meetings
Announced on Meeting on
Jun 16, 2025 Aug 05, 2025
-
Feb 12, 2025 Mar 18, 2025
-
Jun 21, 2024 Jul 22, 2024
-
May 05, 2023 Aug 04, 2023
-
May 10, 2022 Jun 14, 2022
-

Announced on	Ex-Date	Dividend%
May 06, 2025	Jul 29, 2025	550%
May 09, 2024	Jul 15, 2024	550%
May 05, 2023	Jul 28, 2023	400%
May 02, 2022	Aug 17, 2022	500%
May 02, 2022	-	500%

Announced on	Meeting on
Jun 16, 2025	Aug 05, 2025
-
Feb 12, 2025	Mar 18, 2025
-
Jun 21, 2024	Jul 22, 2024
-
May 05, 2023	Aug 04, 2023
-
May 10, 2022	Jun 14, 2022
-

About Alembic Pharma

Alembic Pharmaceuticals Ltd., incorporated in the year 2010, is a Mid Cap company (having a market cap of Rs 14,611.52 Crore) operating in Pharmaceuticals sector.

Alembic Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Other Operating Revenue, Export Incentives and Royalty Income for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 1,873.22 Crore, down .98 % from last quarter Total Income of Rs 1,891.81 Crore and up 5.01 % from last year same quarter Total Income of Rs 1,783.83 Crore. Company has reported net profit after tax of Rs 200.42 Crore in latest quarter.

The company’s top management includes Mr.Chirayu Amin, Mr.Pranav Amin, Mr.Shaunak Amin, Mr.R K Baheti, Mr.Ashok Barat, Ms.Geeta Goradia, Mr.Jai Diwanji, Mr.Manish Kejriwal, Ms.Manisha Saraf. Company has K C Mehta & Co. LLP as its auditors. As on 31-03-2026, the company has a total of 19.66 Crore shares outstanding.

Alembic Pharma Share Price Today is Rs. 743.35. On previous day, the Alembic Pharma Share Price (NSE) closed at Rs. 737.2, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 69.74% of the stake in Alembic Pharma shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Alembic Pharma stocks was 4.26% as compared to 4.23% in Dec 2025 with increase of 0.03%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 16.14% as compared to 16.14% in Dec 2025 with decrease of 0.0%. Out of the total DII holdings in Alembic Pharma shares 8.18% was held by mutual funds. The rest including public held is 9.86%. Alembic Pharma stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Alembic Pharma Dividend: Ever since 2010, Alembic Pharma dividends has been paid out around 18 times. As on 12 Jun, 2026, 03:55 PM IST, The overall dividend yield for Alembic Pharma stands at 1.63%. The last dividend paid was on July 29, 2025 (Rs. 11.0). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 34.33.

Alembic Pharma Bonus: The most recent bonus issue had been in year null around 0 years ago at 0 : 0 ratio. The first bonus issue was announced in null.

Stock Forecast:
After showing 1873.22 Cr. of sales and 0.98% of quarterly net loss, there have been multiple ups and downs in the Alembic Pharma stock prices in the past few weeks. For example, Alembic Pharma stock price on 4th of June 2026 was around Rs. 737.55. Alembic Pharma share price now stands at an average of Rs. 743.35. Judging by last week's performance, stock is in down trend.

Alembic Pharma has a median target price of Rs. 932.64 in 12 months by 11 analysts. They have provided a high estimate of Rs. 1275.0 and low estimate of Rs. 715.0 for Alembic Pharma share.

Historical Prices and Performance:
Alembic Pharma, incorporated in 2010 is a Mid Cap company (with a market cap of Rs. 14440.51) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Alembic Pharma stock was 11.89%, 11.23%, 12.78%, 7.82% and 9.94% respectively.
The Alembic Pharma share gave a 3 year return of 24.61% as compared to Nifty 50 which gave a return of 24.77%.
Alembic Pharma announced 550.0% final dividend on July 29, 2025.

Key Metrics:
PE Ratio of Alembic Pharma is 21.4
Prices/Sales Ratio of Alembic Pharma is 1.77
Price/Book Ratio of Alembic Pharma is 2.55

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Alembic Pharma, major competitors and peers include Wockhardt, Sai Life Science Ltd., Neuland Labs and OneSource Specialty. As of Dec 2025, the dividend yield of Alembic Pharma stands at 1.63% while Wockhardt, Sai Life Science Ltd., Neuland Labs and OneSource Specialty stand at 0.0%, 0.0%, 0.2% and 0.0% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 21.4 and 2.55 respectively.

Leadership of Alembic Pharma :
Manisha Saraf is Co. Secretary & Compl. Officer
Chirayu Amin is Chairman & CEO
Pranav Amin is Managing Director
Shaunak Amin is Managing Director
R K Baheti is Director - Finance & CFO
Jai Diwanji is Independent Director
Ashok Barat is Independent Director
Geeta Goradia is Independent Director
Manish Kejriwal is Independent Director

Industry

Pharma - Indian

Key Indices Listed On

Nifty 500, BSE 500, BSE 250 SmallCap Index, BSE SmallCap, BSE Healthcare

Address

Alembic Road,Vadodra, Gujarat - 390003

Contact

apl.investors@alembic.co.in

http://www.alembicpharmaceuticals.com

PE Ratio(x)	21.65
EPS - TTM(₹)	34.33
MCap(₹ Cr.)	14,611.52
MCap Rank	38
PB Ratio(x)	2.56
Div Yield(%)	1.61
Face Value(₹)	2.00
52W High(₹)	1,107.90
52W Low(₹)	635.80
MCap/Sales	1.77
Beta(1 Month)	0.88
BV/Share(₹)	288.41

PE Ratio(x)	21.56
EPS - TTM(₹)	34.33
MCap(₹ Cr.)	14,544.69
MCap Rank	38
PB Ratio(x)	2.55
Div Yield(%)	1.62
Face Value(₹)	2.00
52W High(₹)	1,107.80
52W Low(₹)	635.30
MCap/Sales	1.77
Beta(1 Month)	0.96
BV/Share(₹)	288.41

1 Day	1.19%
1 Month	-3.23%
3 Months	5.69%
1 Year	-25.11%
3 Years	27.78%
5 Years	-26.11%

1 Day	0.67%
1 Month	-3.7%
3 Months	5.49%
1 Year	-25.31%
3 Years	27.08%
5 Years	-26.45%

R1	752.73	Pivot 741.12	S1	723.03
R2	770.82		S2	711.42
R3	800.52		S3	681.72

Alembic Pharmaceuticals Share Price

Key Metrics

Alembic Pharma share price insights

Alembic Pharma Share Price Returns

Alembic Pharma Share Recommendations

News & Analysis

Financials

Share Price Forecast

Technicals

Peer Comparison

Shareholding Pattern

Mutual Funds Ownership

Kotak Small Cap Direct-G

DSP Midcap Direct-G

ICICI Pru Pharma Healthcare and Diagnostics (P.H.D) Direct-G

Alembic Pharma Futures & Options

Alembic Pharma Top Searches

Corporate Actions

About Alembic Pharma

Executive Leadership

Auditors

FAQs about Alembic Pharma share

Top Gainers

Top Losers

Equity Quick Links

More from Markets

Trending in Markets

Browse Companies

Popular Categories

Hot on Web

In Case you missed it

Top Searched Companies

Latest News